V
Vcanbio Cell & Gene Engineering Corp Ltd
SSE:600645
Vcanbio Cell & Gene Engineering Corp Ltd
SSE:600645
Price:
29.98
CNY
1.32%
Market Closed
Market Cap:
¥14B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
V
|
Vcanbio Cell & Gene Engineering Corp Ltd
SSE:600645
|
CN |
|
Bitfarms Ltd
XTSX:BITF
|
CA |
|
G
|
Glacier Bancorp Inc
NYSE:GBCI
|
US |
|
Bank Aljazira SJSC
SAU:1020
|
SA |
|
Doma Holdings Inc
NYSE:DOMA
|
US |
Relative Value
The Relative Value of one Vcanbio Cell & Gene Engineering Corp Ltd stock under the Base Case scenario is hidden CNY. Compared to the current market price of 29.98 CNY, Vcanbio Cell & Gene Engineering Corp Ltd is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Vcanbio Cell & Gene Engineering Corp Ltd Relative Value
HIDDEN
Multiples Across Competitors
Competitors Multiples
Vcanbio Cell & Gene Engineering Corp Ltd Competitors
Vcanbio Cell & Gene Engineering Corp Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
V
|
Vcanbio Cell & Gene Engineering Corp Ltd
SSE:600645
|
14B CNY | 9.5 | 187.7 | 101.6 | 101.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.5B USD | 5.9 | 86.5 | 14.4 | 20 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD | 5.1 | 24.5 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.3B USD | 5.8 | 20.1 | 12.5 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.3B USD | 9.6 | 29.1 | 21.9 | 22.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.5B USD | 5.5 | 17.4 | 12.8 | 14.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.8B AUD | 3.1 | 34.3 | 11.3 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
41.3B USD | 11.2 | 132.1 | 73.9 | 82.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
